Connection

VINCENT TAM to Acinetobacter baumannii

This is a "connection" page, showing publications VINCENT TAM has written about Acinetobacter baumannii.
Connection Strength

8.391
  1. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.
    View in: PubMed
    Score: 0.865
  2. Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A?case report. Pharmacotherapy. 2025 01; 45(1):66-69.
    View in: PubMed
    Score: 0.831
  3. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 09; 38:252-255.
    View in: PubMed
    Score: 0.808
  4. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2).
    View in: PubMed
    Score: 0.734
  5. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
    View in: PubMed
    Score: 0.723
  6. Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0199621.
    View in: PubMed
    Score: 0.670
  7. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.
    View in: PubMed
    Score: 0.586
  8. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).
    View in: PubMed
    Score: 0.490
  9. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
    View in: PubMed
    Score: 0.422
  10. Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44.
    View in: PubMed
    Score: 0.403
  11. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother. 2012 Apr; 67(4):928-32.
    View in: PubMed
    Score: 0.340
  12. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5.
    View in: PubMed
    Score: 0.330
  13. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis. 2010 Mar 15; 201(6):889-97.
    View in: PubMed
    Score: 0.300
  14. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93.
    View in: PubMed
    Score: 0.269
  15. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008 Aug; 52(8):2898-904.
    View in: PubMed
    Score: 0.264
  16. Pharmacokinetics of sulbactam-durlobactam in patients with Acinetobacter baumannii ventriculitis: a report of two cases. Antimicrob Agents Chemother. 2025 11 05; 69(11):e0067425.
    View in: PubMed
    Score: 0.220
  17. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1.
    View in: PubMed
    Score: 0.082
  18. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.